AXGN — Q2 2026 Financial Report Analysis

Sales up 23%, but a costlier product mix and a 30% jump in operating costs pushed Axogen back to a loss

Axogen sells products surgeons use to repair damaged peripheral nerves — the nerves outside the brain and spinal cord that carry feeling and movement to the hands, face and body. Its main product is Avance, a processed human-donor nerve used to bridge a gap in an injured nerve. In the second quarter of 2026 (April–June), revenue rose 23.1% to $69.7 million, and management raised its full-year sales target for the second time this year. But gross margin slipped, operating expenses grew faster than sales, and the company swung from a $0.6 million profit a year ago to a $1.5 million net loss.

At a glance

• Revenue $69.7M, +23.1%. The 10-Q attributes the growth to more units sold plus price increases, across all three target markets (hand/arm surgery, mouth/jaw/head-and-neck surgery, and breast reconstruction). Breast grew more than 50%.
• Gross margin 72.7%, down from 74.2%. Gross margin is the share of each sales dollar left after the cost of making the product. It fell because Avance became a more expensive-to-make licensed biologic from April 2026, and because breast procedures use longer, costlier grafts.
• Operating loss of $2.2M vs a $1.7M profit a year ago. Operating costs rose 30.9% against 23.1% sales growth. Stock-based pay and higher headcount account for most of the increase.

Key figures

"n/m" = not meaningful: a percentage change from a profit to a loss doesn't tell you anything useful. Adjusted figures are the company's own; they add back stock-based compensation (and, for the half year, the debt payoff loss).

Where the growth came from

The 10-Q says revenue growth was "primarily driven by an increase in unit volume and the impact of changes in price," and that year-to-date growth was broad-based across Extremities (hand, wrist and arm surgery), Oral Maxillofacial & Head and Neck, and Breast. Management credits three things: revenue per customer account up more than 20%, a larger sales force reaching more hospitals, and better insurance coverage and payment for nerve repair.

Breast is the standout. Axogen's Resensation procedure uses nerve grafts to try to restore feeling in the chest after mastectomy and reconstruction, and that business grew more than 50% year over year. The half-year picture is consistent with the quarter: revenue of $131.2M for January–June was up 24.7%.

Why margin went the wrong way

Two separate things pushed the cost of each sale up:

1. Avance became a licensed biologic. The FDA approved Axogen's Biologics License Application (BLA) for Avance on December 3, 2025. A BLA is the full approval route for biological products. It protects Avance from cheaper copies, but the 10-Q says the "higher-cost biologic Avance product" started selling in April 2026, so Q2 was the first full quarter on the higher cost base.
2. Mix toward breast. Breast reconstruction uses longer Avance grafts, which cost more to produce.

Lower inventory write-offs offset part of this. The sequential change shows the size of the hit: gross margin was about 75.2% in Q1 2026 (implied from the half-year and Q2 figures) and 72.7% in Q2, a 2.5-point drop in one quarter. Management's full-year gross margin guidance confirms it. In April the company guided to 74–76%; in July it lowered that to "at least 73%."

Below gross profit, total operating expenses rose $12.5M (+30.9%) to $52.8M. The 10-Q's breakdown:

• $6.4M more in compensation (salaries, commissions, benefits) from more staff and higher sales
• $3.1M more in stock-based compensation. Most of this is performance share awards now expected to pay out above target because sales are running ahead of plan.
• $1.1M more in R&D project costs, mainly clinical trials

General and administrative costs rose fastest, up 38.4%.

What the headline numbers hide

• The net loss would have been bigger without the debt payoff. In January Axogen sold 4.6 million new shares at $31 (about $133M net) and used part of the money to repay its $48.6M Oberland Capital loan early. Quarterly interest expense fell from $2.0M to almost zero, and interest earned on cash rose by $0.6M. Other income therefore improved by $1.7M year over year. At the operating level, before interest, results went from +$1.7M to -$2.2M, a $3.8M decline.
• Adjusted EPS was flat while adjusted net income rose 28%. Adjusted net income grew from $5.7M to $7.3M, but the share count grew about as fast. The adjusted diluted share count was 59.6 million, against about 48.0 million diluted shares a year earlier, because of the January offering plus stock awards and option exercises. So adjusted EPS stayed at $0.12. The gap between GAAP (-$0.03) and adjusted ($0.12) is almost entirely stock-based pay of $8.8M in the quarter, up from $5.2M. That is a real cost to shareholders through dilution, even though no cash is spent.
• The half-year loss includes a large debt-payoff charge. The January–June net loss of $21.1M includes a $16.8M "loss on extinguishment of debt" from repaying the Oberland loan. That charge is a one-off. But the company paid $20.5M in cash fees to the lender, recorded under financing activities rather than operating activities, so it is not just an accounting entry.
• Cash flow improved, partly from timing. Operating cash flow for the half year was +$8.8M, against -$5.4M a year earlier. Free cash flow (operating cash flow minus spending on equipment and intangibles) was +$4.1M, against about -$7.2M. Accounts payable and accrued expenses, though, added $7.1M to cash this year after taking $5.8M away last year. That $12.9M swing in bills and accruals still to be paid explains most of the improvement, and it can reverse.
• Receivables are growing faster than sales. Accounts receivable (money customers owe) rose 30% from December to $34.1M, and inventory rose 12% to $47.3M. Year-to-date sales grew 24.7%. The gap isn't alarming, but it's worth watching.
• The balance sheet is now debt-free. Cash, restricted cash and investments were $113.4M at June 30, up $9.8M from March, with no long-term debt left.

Takeaway: Demand is not the issue: sales are growing in the mid-20s and the full-year target has been raised twice. The issue is that each extra dollar of sales is costing more to deliver. Biologic-licensed Avance and long breast grafts lowered gross margin by about 2.5 points in a single quarter, and operating costs are growing about 8 points faster than revenue. Profitability is falling as the company grows.

Outlook

Guidance (July 29, 2026): full-year revenue growth of at least 24%, or at least $279M, raised from at least 20% / $270M in April. Gross margin of at least 73%, lowered from 74–76%, and positive free cash flow for the year. With $131.2M booked in the first half, the target requires at least about $148M in the second half.

Since the quarter ended, Axogen has made its largest acquisition. On September 10 it agreed to buy BioCircuit Technologies, maker of NerveTape — the first FDA-cleared device for repairing nerves without microsutures (the tiny stitches surgeons normally use) — for $200M in cash, funded by a new share offering announced the same day. The deal closed October 1. Management expects BioCircuit to add about $6M of revenue in Q4 2026 and about $34M in 2027, and says neither figure is included in the 24% growth guidance. It also says the deal will increase adjusted EBITDA margin and adjusted EPS in its first year.

Our read: The revenue story looks durable. Growth is coming from several markets at once, insurance coverage is improving, and the breast business is still expanding quickly. The margin story is the weak point. The lower gross margin from the BLA cost base is likely permanent rather than a one-quarter blip, and the company is still adding sales staff, so operating leverage depends on sales productivity outrunning hiring. For Q3, watch three things: whether gross margin holds at or above the 73% floor, whether operating-expense growth slows toward the revenue growth rate, and whether the free-cash-flow improvement survives once the payables timing benefit fades. From Q4, BioCircuit will make the reported figures harder to compare. The NerveTape revenue will be visible, but so will deal costs and the dilution from the September share sale.

Source: Axogen Form 10-Q for the quarter ended June 30, 2026 (filed July 29, 2026), the Q2 2026 earnings release, and Axogen's 8-K filings of September 10 and October 1, 2026. All figures are from the company's filings; Q1 2026 gross margin is derived from the reported half-year and Q2 figures.